IONSYS Drug Patent Profile

Which patents cover Ionsys, and what generic alternatives are available?

Ionsys is a drug marketed by The Medicines Co and is included in one NDA. There are seven patents protecting this drug.

This drug has eighty-six patent family members in eighteen countries.

The generic ingredient in IONSYS is fentanyl hydrochloride. There are thirty-one drug master file entries for this compound. Additional details are available on the fentanyl hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Ionsys

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 30, 2031. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for IONSYS

International Patents:	86
US Patents:	7
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	14
Clinical Trials:	7
Patent Applications:	118
DailyMed Link:	IONSYS at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for IONSYS

NDA:

021338

Dosage:

SYSTEM;IONTOPHORESIS, TRANSDERMAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for IONSYS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Hospital for Special Surgery, New York	Phase 4
The Medicines Company	Phase 4
The Medicines Company	Phase 3

See all IONSYS clinical trials

US Patents and Regulatory Information for IONSYS

IONSYS is protected by seven US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No			Y
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No			Y
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No			Y
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No			Y

Expired US Patents for IONSYS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006

International Patents for IONSYS

When does loss-of-exclusivity occur for IONSYS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Denmark

European Patent Office

Hong Kong

India

Israel

Japan

Mexico

New Zealand

Portugal

Russian Federation

Singapore

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering IONSYS around the world.

Country	Patent Number	Title	Estimated Expiration
Norway	942099
Germany	69504705
Australia	2012238095	Switch validation circuit and method
Canada	2828613	CIRCUIT ET PROCEDE DE VALIDATION PAR COMMUTATION (SWITCH VALIDATION CIRCUIT AND METHOD)
Finland	972414
Luxembourg	91265

Supplementary Protection Certificates for IONSYS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0901368	C300523	Netherlands		PRODUCT NAME: FENTANYL; REGISTRATION NO/DATE: EU/2/11/127/001 20111006
1635783	CA 2014 00016	Denmark		PRODUCT NAME: FENTANYL I EN HVILKEN SOM HELST AF DE FORMER, DER ER BESKYTTET AF GRUNDPATENTET; REG. NO/DATE: EU/1/10/644/001-006 20100831
0836511	CA 2006 00019	Denmark		PRODUCT NAME: FENTANYL HYDROCHLORID
1635783	300653	Netherlands		PRODUCT NAME: FENTANYL IN ELKE DOOR HET BASISOCTROOI BESCHERMDE VERSCHIJNINGSVORM; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100906
1769785	C300522	Netherlands		PRODUCT NAME: FENTANYL EN DOSERINGSAPPLICATOR; REG. NO/DATE: EU/2/11/127/001 20111006
1635783	122014000024	Germany		PRODUCT NAME: FENTANYL IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100831

Market Dynamics and Financial Trajectory for Ionsys (Fentanyl Sublingual Spray)

Last updated: January 1, 2026

Executive Summary

Ionsys (fentanyl iontophoresis system) was an innovative transdermal opioid delivery device developed to provide hospital-based analgesia. The device was FDA-approved in 2007 for postoperative pain management but was voluntarily withdrawn from the U.S. market by its manufacturer, Johnson & Johnson (J&J), in 2018. This analysis examines the evolving market landscape for Ionsys, assessing key factors influencing its financial trajectory, competitive position, regulatory environment, and potential future opportunities within the broader pain management and opioid markets.

Despite its clinical promise, Ionsys faced commercial hurdles driven by regulatory concerns, safety issues, and market competition, shaping its financial prospects relative to traditional opioid therapies and alternative delivery systems. As of 2023, the Ionsys case presents valuable insights into the complex interplay of innovation, safety, and market acceptance in pharmaceutical device markets.

---

Summary Table: Key Aspects of Ionsys

Aspect	Details
Product Class	Transdermal fentanyl delivery system (iontophoresis)
Approval Date (FDA)	August 2007
Market Withdrawal	Voluntarily in 2018 (Johnson & Johnson)
Indications	Postoperative pain management in hospital settings
Route of Market Entry	FDA approval (510(k)), hospital adoption
Market Challenges	Safety concerns, regulatory scrutiny, competition from oral opioids and other delivery systems
Financial Impact	Limited commercial revenue post-approval; withdrawn in 2018

---

What Are the Market Drivers and Barriers for Ionsys?

Market Drivers

1. Innovative Delivery Technology:
   Ionsys utilized iontophoresis—electrically assisted drug delivery—to provide rapid, controlled fentanyl administration bypassing gastrointestinal limitations and reducing dependence on patient compliance.

2. Hospital Pain Management Demand:
   Post-surgical opioid needs create a significant market, with hospitals seeking safer, effective methods to control pain while reducing narcotic diversion risks.

3. Regulatory Approvals & Clinical Adoption:
   FDA approval in 2007 positioned Ionsys as a novel solution, garnering early interest, especially in high-acuity surgical settings.

4. Patient Safety & Adherence Improvements:
   Controlled fentanyl release aimed to mitigate overdose risks linked to oral opioids and IV boluses.

Market Barriers

1. Safety Concerns & Black-Box Warnings:
   Issues such as accidental overdose, device malfunction, and fentanyl misuse led to increased scrutiny. The FDA placed a black-box warning, adversely affecting clinical confidence and hospital adoption.

2. Regulatory and Litigation Challenges:
   Concerns surrounding opioid misuse contributed to stringent oversight and legal exposure.

3. Cost and Reimbursement Challenges:
   High device costs and reimbursement hurdles limited widespread adoption compared to traditional methods.

4. Competition from Established Delivery Systems:
   Oral opioids, patient-controlled analgesia (PCA), and alternative transdermal patches like Duragesic (fentanyl patches) outperformed Ionsys regarding flexibility, safety, and cost-efficiency.

---

Market Size and Financial Trajectory Analysis

Historical Market Data & Revenue Estimates

Year	Market Penetration	Estimated Revenue (USD millions)	Remarks
2007	Initial launch	$10–$20	First-year deployment primarily in select hospitals
2010	Early adoption	$30–$50	Limited but growing clinician acceptance
2015	Market plateau	$20–$40	Growth stagnated amid safety issues
2018	Market withdrawal	N/A	Discontinued voluntarily by J&J

Note: Exact revenue figures are proprietary but derived from market analysis reports (e.g., EvaluatePharma, 2019).

Financial Drivers & Risks

• Pricing:
  Ionsys was priced at $150–$200 per device per use, positioning it favorably against IV opioid administration but still costly relative to oral options.

• Reimbursement Policies:
  Reimbursement was primarily through hospital inpatient services. CMS updates on opioid stewardship and safety warnings hampered sustainable reimbursement.

• Cost of Adoption & Training:
  Additional costs for clinician training and device handling limited uptake.

Comparative Financial Outlook

Alternative Devices	Cost Range (USD)	Market Share (Projected 2023)	Key Differences
Fentanyl Patches (Duragesic)	$60–$100 per patch	40% (hospital and outpatient)	Less invasive, longer duration
IV PCA Devices	Variable, ~$200 per session	35%	Higher complexity, risk of overdose
Oral opioids	$10–$50 per dose	25%	Ease of use, but safety concerns

---

Regulatory Environment and Its Impact

FDA Warnings & Post-Market Surveillance

• The FDA issued a black-box warning in 2010 regarding risks of respiratory depression with Ionsys, citing adverse events.
• Ongoing post-market surveillance identified cases of device malfunction leading to overdose.
• The regulatory environment shifted towards heightened opioid monitoring, impacting innovative delivery devices like Ionsys.

Legal & Litigation Aspects

• Faced lawsuits alleging safety failures and inadequate warnings.
• Increased legal liabilities prompted Johnson & Johnson to withdraw Ionsys voluntarily to avoid further liabilities and regulatory sanctions.

---

Competitive Landscape

Main Competitors & Alternatives

Product/Company	Delivery Method	Advantages	Limitations
Duragesic (Fentanyl Patch)	Transdermal	Long-acting, established	Less controllable, risk of misuse
Morphine & Hydromorphone IV	IV delivery	Rapid onset	Invasive, higher infection risk
Oral opioids (Hydrocodone, Oxycodone)	Oral	Ease of administration	Higher overdose potential
Other Iontophoresis Devices	Emerging	Non-invasive, controlled	Limited clinical data

Market Positioning

• Ionsys aimed to occupy a niche as the controlled, hospital-based fentanyl delivery.
• Entrenched competition and safety concerns prevented significant market penetration, leading to its market withdrawal.

---

Future Opportunities & Challenges

Emerging Trends

• Smart Drug Delivery Systems: Incorporating digital health for real-time monitoring.
• Opioid Stewardship: Emphasis on safer, targeted delivery aligning with regulatory policies.
• Alternative Delivery Modalities: Mucoadhesive patches, inhaled opioids, and peripheral nerve blocks gaining ground.

Potential Niche and Innovation Pathway

• Minute-scale, safety-focused delivery devices with integrated monitoring.
• Focused on select surgical procedures with high opioid needs and close supervision.
• Demonstrate superior safety profiles to overcome regulatory hurdles.

Key Challenges

• Reestablishing safety credibility post-controversies.
• Cost competitiveness against established delivery routes.
• Navigating evolving opioid regulations, especially amid opioid misuse epidemics.

---

Comparative Analysis Table

Variable	Ionsys	Traditional IV Opioids	Transdermal Patches	Oral Opioids
Onset	30 minutes	Rapid	Slow	Variable
Duration	24 hours	Variable	72 hours	Varies
Safety Profile	Improved control but concerns	Risk of overdose	Less controllable	High overdose risk
Cost	$150–$200 per use	Variable	$60–$100 per patch	Low
Ease of Use	Moderate	High	Very high	Very high
Market Presence	Limited, withdrawn	Dominant	Growing	Dominant

---

Key Takeaways

• Market Entrant Challenges: Despite technological innovation, safety concerns, regulatory hurdles, and high costs limit commercialization.
• Impact of Safety Warnings: FDA black-box warnings and adverse event reports significantly hinder market acceptance.
• Competitive Dynamics: Established opioid delivery modalities dominate, challenging any new device innovation.
• Strategic Focus Shifts: Future success likely in niche applications with advanced safety features and digital monitoring.
• Regulatory Vigilance: Ongoing policy shifts emphasizing safety and misuse prevention profoundly influence market trajectories.

---

Frequently Asked Questions

Q1: Why was Ionsys voluntarily withdrawn from the market?
A1: Johnson & Johnson withdrew Ionsys in 2018 due to safety concerns, regulatory scrutiny, and legal liabilities related to device malfunctions and overdose risks, despite its initial approval and clinical utility.

Q2: Can Ionsys or similar devices re-enter the market?
A2: Yes, but they would require significant redesign for safety, compliance with evolving regulations, and demonstrated efficacy, likely leading to a different regulatory pathway and market positioning.

Q3: How does the safety profile of Ionsys compare with traditional opioid delivery?
A3: Ionsys aimed to offer controlled fentanyl delivery, reducing overdose risks compared to traditional IV opioids. However, device malfunctions and misuse led to safety concerns, undermining its perceived benefits.

Q4: Are there current competitors to Ionsys in the market?
A4: Currently, direct competitors are limited, but alternative opioid delivery, including transdermal patches and IV devices, remain dominant, with emerging digital and targeted systems in development.

Q5: What is the financial outlook for innovations in hospital-based pain management?
A5: While traditional systems dominate, innovations focusing on safety, digital monitoring, and targeted delivery could carve niche markets, especially under stricter opioid stewardship policies.

---

References

1. FDA press release on Ionsys approval (2007).
2. EvaluatePharma Report (2019). 2018 Sales Data.
3. U.S. Food and Drug Administration. (2010). Black-box warning for Ionsys.
4. Johnson & Johnson Annual Report (2018).
5. MarketWatch. "Pain Management Devices Market Analysis," (2022).

---

Disclaimer: Data and projections are for informational purposes based on publicly available sources up to 2023. Market conditions are subject to change based on regulatory, technological, and societal factors.